Stocks Health care FATE
NASDAQ · Health careFate Therapeutics Inc (FATE)
Fate Therapeutics Inc brought in $6.5M of revenue over the twelve months to June 30, 2026, down 23.4% from a year earlier. It posted a net loss of $126M. In fiscal 2025 capital spending exceeded operating cash flow by $112M. At June 30, 2026 it held $32.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Fate Therapeutics Inc does
Fate Therapeutics Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FATE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.6M | -$136.3M | -$1.15 | -$112M |
| 2024 | $13.6M | -$186.3M | -$1.64 | -$123.6M |
| 2023 | $63.5M | -$160.9M | -$1.64 | -$138.4M |
| 2022 | $96.3M | -$281.7M | -$2.91 | -$283.8M |
| 2021 | $55.8M | -$212.2M | -$2.24 | -$213.6M |
| 2020 | $31.4M | -$173.4M | -$2.10 | -$44.2M |
Latest SEC filings
What Fate Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 15, 2026
- June 4, 2026Other event 8-K
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026
- May 13, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
Questions about FATE
What does Fate Therapeutics Inc do?
Fate Therapeutics Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FATE.
Is Fate Therapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $126M on revenue of $6.5M.
How much revenue does Fate Therapeutics Inc make?
Over the twelve months to June 30, 2026 Fate Therapeutics Inc reported revenue of $6.5M. That is 23.4% less than a year earlier.
When did Fate Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow FATE
Get an email when Fate Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow FATE: get an email when it filesWhere the numbers come from
Financial figures are the values Fate Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.